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Summary 
Schistosomiasis  is a parasitic disease affecting ~200 million people, primarily in the third world. 
Sckistosoma mansoni, one of the causative agents of this disease, parasitize the human mesenteric 
and portal blood systems while successfully evading host immune responses.  During parasite 
penetration into the mammalian host and shortly afterwards, the larvae rapidly convert from 
being sensitive  to being resistant to C-mediated killing. Treatment of the C-resistant parasitic 
forms with trypsin renders the parasite susceptible to C attack, thus indicating the presence of 
C inhibitory protein(s) on the parasite surface. We describe here an intrinsic schistosome C inhibitory 
protein (SCIP-1)  that exhibits antigenic and functional similarities with the human C-inhibitor 
CD59. Like CD59, SCIP-1 is capable of inhibiting formation of the C membrane attack complex 
(MAC), probably by binding to C8 and C9 of the C  terminal pathway. In addition,  SCIP-1 
is apparently also membrane-anchored via glycosyl phosphatidylinositol as it can be specifically 
released with phosphatidylinositol-specific phospholipase C. Soluble SCIP-1, partially purified 
from Nonidet P-40 extracts of schistosome tegument is capable of inhibiting hemolysis of sensitized 
sheep erythrocytes and of rabbit erythrocytes by human C. Anti-human CD59 antibodies block 
this activity of SCIP-1 and in addition, upon binding to intact parasites,  render them vulnerable 
to killing by human and guinea pig C.  SCIP-1 is located on the surface of C-resistant forms 
of the parasite,  i.e.,  24-h cultured mechanical schistosomula and in vivo-derived adult worms 
as revealed by immunofluorescence and immunogold electron microscopy studies. These results 
identify one of the mechanisms schistosomes use to escape immune attack. 
S 
chistosoma mansoni is a blood fluke that successfully par- 
asitizes  pulmonate  snails  and  mammalian  hosts  (1). 
Efficient evasion of the mammalian host's C system is there- 
fore essential for parasite survival. During penetration of the 
mammalian host's skin, the young schistosomula are sensi- 
tive to the cytolytic action of the C  system. These young 
larvae rapidly transform and undergo many morphological 
changes, resulting in a form that is highly resistant to C at- 
tack (reviewed in 2). The later developmental stages of the 
parasite,  i.e.,  the lung and adult worms, found in the lung 
and mesenteric veins,  respectively, also show refractoriness 
to C killing (3, 4). The freshly transforming schistosomula 
use several evasion  strategies to resist C  damage. First, the 
schistosomula shed their glycocalyx coat which is a strong 
activator of the alternative C pathway (5, 6). Consequently, 
Part of the results  were  presented  at the 14th International  Complement 
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the schistosomula become weak activators of the alternative 
C  pathway. Second, due to this release of the C  activating 
glycocalyx, there is consumption of C components at a site 
distant  to  the  parasite's  cell  membrane  (7).  A  28-kD 
schistosomular serine protease, which is released from the 
acetabular glands of transforming cercaria and is expressed 
later on the surface membrane of schistosomula and adult 
worms, probably plays a dual role in C resistance. The pro- 
tease accelerates the release of the glycocalyx (8), and cleaves 
certain C  proteins (9-11). By degrading C  components in 
plasma or on the cell surface,  such a protease may protect 
the parasite  from C opsonization and lysis. Another protec- 
tive mechanism employed by S. mansoni is the use of C regula- 
tory proteins. Initial studies performed by us indicated the 
existence of surface proteins which, upon removal by trypsin 
or pronase, render the parasite susceptible to C  attack (12). 
Recently, our results have indicated that schistosomula and 
adult worms express two C inhibitors, one acting at the C3 
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script in preparation), and one acting at the C8/C9 step of 
the C  cascade  (see below). 
Five plasma C proteins (C5, C6, C7, C8, and C9) partici- 
pate in formation of the membrane attack complex of C 
(MAC) 1 on activating surfaces (13). This process may be re- 
stricted on homologous cells by several membrane proteins, 
such as homologous restriction factor (HRF, C8-binding pro- 
tein, MAC-inhibiting protein) (14-16)  and CD59 (17-23). 
CD59 is an 18-20-kD membrane protein widely distributed 
in many human tissues (24, 25) and released in a soluble form 
in human urine (17). Two nonmammalian proteins with partial 
homology to human CD59 have been described.  One is an 
adhesion molecule ofEntamoeba histolytica (27) and the second 
one is a gene product of Herpesvirus saimiri (28). 
In this report we describe a schistosome C inhibitory pro- 
tein type I (SCIP-1) that is a 94-kD protein functionally  and 
antigenically related to human CD59. We demonstrate that 
several properties of CD59,  such as the capacity to inhibit 
formation of C MAC and the binding of human C8 and C9 
components (23,  29, 30) are manifested by SCIP-1 as well, 
and that both molecules are,  apparently, external glycosyl 
phosphatidylinositol-anchored membrane proteins (31). Fur- 
thermore, antibodies directed to human CD59 bind to SCIP-1 
and render the parasite  susceptible  to C-mediated killing. 
Materials and Methods 
Parasites and Parasite Extracts.  A Puerto Rican strain of S. man- 
soni was maintained in Biomphalaria glabrata snails and outbred ICR 
mice. Cercaria were collected after a 90-rain shedding period and 
mechanically transformed  by  passage between  two  connected 
syringes (32). They were washed immediately  with ice cold defined 
synthetic medium (DSM) composed  of a 1:1 mixture of  RPMI 1640 
and nutrient F12 (GIBCO BRL, Gaithersburg, MD) supplemented 
with  100  U/ml  penicillin, 100  /~g/ml  streptomycin,  2  mM 
t-glutamine (Kibbutz Beth Haemek, Israel), and 20 mM Hepes 
buffer, pH 7.2. The tails and bodies were separated  by centrifuga- 
tion through a 61% Percoll (Pharmacia LKB, Uppsala, Sweden) 
solution. The schistosomula were washed several times in DSM 
and cultured for 24 h in DSM at a concentration of 20,000/well 
in a 24-well plate (Falcon Labware, Oxnard, CA) in a humidified, 
6% CO2 incubator. Lung stage worms of S.  mansoni were ob- 
tained by lung/heart perfusion of ICR mice infected with 3,000 
cercaria by subcutaneous  injection 6 d earlier. The perfusion  medium 
was DSM supplemented with 10 U/ml Heparin (Sigma Chemical 
Co., St. Louis, MO). The perfused lungs and hearts were washed 
several times, finely minced, and incubated for 3 h at 37~  The 
suspension was filtered  through a Nitex-132 mesh nylon sieve (Tetko, 
Rolling Meadows, IL) and the lung worms recovered by centrifu- 
gation at 120 g for 3 rain. Adult worms (AW) of S. mansoni were 
isolated by perfusion of the hepatic portal system of Syrian gold 
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hamsters infected  6 wk earlier  with 1,000 cercaria by the ring method 
(33). The perfusion medium was DSM supplemented with 500 
U/ml Heparin. 
NP-40-released Material (NPRM) Preparation.  One million 24- 
h-old schistosomula or 2,000 AW were incubated in I ml NP-40 
(1%) (Sigma Chemical Co.) in PBS for 2 h on ice. The schistoso- 
mula and AW remained intact and were removed by centrifuga- 
tion and the supernatant was further cleared by centrifugation in 
an Airfuge (Beckman Instruments, Inc., Fullerton, CA) at 10  s g. 
The resulting supernatant  was mixed and gently agitated  with SM-2 
beads (Bio-Rad  Laboratories,  Richmond, CA) according  to manufac- 
turer's instructions, for removal  of  the NP-40. The resulting NPRM 
was stored in aliquots at  -70~ 
Trypsin-released Material (TRM) Preparation.  3  x  10  s 24-h-old 
schistosomula or 1,000 AW were treated with 100 #g/ml or 500 
#g/ml trypsin (TPCK-treated; Sigma Chemical Co.), respectively, 
in DSM for 30 min at 24~  The parasites were removed  by cen- 
trifugation and soybean trypsin inhibitor (Sigma Chemical Co.) 
was added (twice the concentration of trypsin) to the supernatant 
for inhibiting further trypsin activity. 
Sera andAntisera.  Normal human serum (NHS) was obtained 
from healthy donors. C7- and C8-deficient  human sera (C7d-NHS 
and C8d-NHS) were prepared from two donors who are geneti- 
cally deficient in C  components C7 and C8,  respectively (34). 
Normal rabbit serum (NRbS) and guinea pig serum (GPS) were 
prepared from healthy animals and C4-deficient GPS (C4d-GPS) 
from genetically C4-deficient guinea pigs. Animals were provided 
by the Animal Breeding Center of the Weizmann Institute  of 
Science. All sera were aliquoted and kept at  -70~  until used. 
Anti-CD59 monospecific  polyclonal  Abs were prepared in rabbits 
by three subcutaneous injections of 20 #g purified human urine 
CD59 at 2-wk intervals. F(ab')2 fragments and rat mAb YTH 53.1 
anti-human CD59, were prepared as described  elsewhere (17). Abs 
to schistosomular TRM (anti-TRM Abs) were obtained as previ- 
ously described (12). 
Labeling Procedures.  Schistosomula  were surface  iodinated using 
the lactoperoxidase technique (35) and Na12SI (Amersham Inter- 
national, Amersham, UK). Freshly  transformed  schistosomula  were 
metabolically labeled in methionine-free DME  (GIBCO  BRL) 
(20,000 schistosomula/ml in a 24-well tissue culture plate) sup- 
plemented with [3SS]methionine (50 #Ci/ml) (Amersham Inter- 
national, 1 Ci/#mole) for 24 h. Protein A (Sigma Chemical Co.) 
and purified  human C9 (36) were iodinated by the Iodogen method 
(37) using Iodogen reagent (Pierce Chemical Co., Rockford, IL) 
and NalZSI (Amersham International). 
C9 Deposition on Schistosomula.  Schistosomula  (15,000) were in- 
cubated in  100 #1 NHS  supplemented with 125I-C9 for various 
times at 37~  (12 #g nsI-C9 were introduced to 1 ml of NHS; 
20% of native C9). The schistosomula were washed four times 
with DSM and boiled for 10 rain in reducing sample buffer (50 
mM Tris, pH 6.8, 10% glycerol, 4% SDS and 5% B-mercapto- 
ethanol) containing protease inhibitors (10 #g/ml Soybean  trypsin 
inhibitor;  5  mM  PMSF;  1 mM Diisopropyl fluorophosphate; 
10 mM EDTA). The schistosomula were then sonicated in a bath 
sonicator (Heat System;  Ultrasonic, Inc., Farmingdale,  NY) at 4~ 
for 3 rain, three times, with attenuated vortexing. The resulting 
extracts were applied on a 2.5-10%  gradient acrylamide gel for 
SDS-PAGE analysis (38). 
Hemolytic Assays.  Sensitized  sheep erythrocytes  (EAs) were pre- 
pared as previously  described (39) with rabbit hemolysin (DIFCO, 
Detroit, MI). The EAs were washed twice with GVB  2+ (veronal- 
buffered saline, pH 7.4, containing 0.1% gelatin, 0.5 mM MgC12, 
0.15 mM CaCI~, and 0.02% NAN3), brought to a concentration 
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on the classical pathway of C,  1.5  x  107 EAs were incubated at 
37~  for 30 min in 100 #1 GVB  2+ containing a dilution of NHS 
(usually 1:200) giving 50% cell lysis, with or without parasite TRM 
or NPRM.  Cell lysis was stopped by adding  1 ml of cold GVB 
and centrifugation at 500 g and percent hemolysis was determined 
by measuring spectroscopically the supernatant at 412 nm. Activity 
of the C alternative pathway was assayed using fresh rabbit erythro- 
cytes (ER), 1.5  x  107 Er~ were incubated for 30 min at 37~  in 
100/~1 GVB  2+ containing 5 mM MgC12,  10 mM EGTA, and 6 
#1 NHS. Cell lysis was stopped by adding I ml of cold GVB con- 
taining 10 mM EDTA. Percent hemolysis in absence or presence 
of parasite TRaM or NPRM was determined as described above. 
To measure the effect of parasitic extracts on the preformed C5b-7 
complex, EAs (109/ml)  were incubated first with 400 #1 of 1:20 
diluted C8d-NHS for 15 min at 37~  and washed twice with cold 
GVB  2+.  1.5  x  107 EAC5b-7  were incubated  with  or without 
parasite NPRM  for  15  min  at  24~  washed  twice with  cold 
GVB  2§ containing 10 mM EDTA, and incubated with C7d-NHS 
(diluted 1:2,000  in GVB), as the source of C components C8 and 
C9,  for 30 min at 37~ 
Killing of Parasites by C.  200 schistosomula or lung worms (in 
20/~1) were transferred into wells of 96-weU microtiter plates (Nunc, 
Roskilde, Denmark) and 10 AW were transferred into polystyrene 
tubes (12  x  75 mm; Falcon Labware). The parasites were then 
mixed with 100/~1 of NHS, GPS (diluted 1:2), or C4d-GPS (diluted 
1:2) and incubated for 18 h at 37~  in a humidified incubator with 
6% CO2. Heat inactivated (30 min at 56~  sera served  as con- 
trol.  Mortality was determined under a stereoscopic microscope 
based on lack of parasite motility and granular and opaque appear- 
ance. Experiments were run in duplicates.  Percent mortality in con- 
trol cultures  (Cn) was subtracted from that of experimental (E) 
and percent net mortality was calculated according to the formula: 
%  net mortality  =  (E  -  Cn)/(100  -  Cn)  x  100. 
Antigenic Competition Assay.  A 96-well microtiter plate (Micro- 
Test Flexible Assay Plate; Falcon Labware) was coated with schisto- 
somular NPRM (15/~g/100/xl  PBS/well) for 3 h  at 24~  The 
plate was washed and uncoated areas were blocked with PBS-0.5 % 
gelatin for 1 h at 24~  Polyclonal  anti-human CD59 antiserum, 
as such or preincubated with the competing substance, was added 
at various dilutions in PBS to the microtiter plate for 2.5 h at 24~ 
and for 18 h at 4~  After three washes with PBS, 12sI-Protein A 
(120,000 cpm/well) in PBS-0.1% gelatin was added for 3 h at 24~ 
After an additional three washes, the plate was dried and wells were 
cut  and counted  in  a  Packard  q'-counter  (Packard  Instruments, 
Chicago,  IL). Competition was effected by preincubation of the 
anti-CD59  antiserum  with  purified  human  urine  CD59  (200 
rig/well), human E ghosts (prepared according to reference 40) (4.8 
/xg/well),  schistosomular NPRM (15/xg/well), or with buffer alone 
as control,  for 2 h  at 37~ 
Immunofluorescenc~  Schistosomula (3,000-5,000)  or AW (10-20) 
were washed in DSM containing 0.5% BSA and 0.1% 3' globulin 
(Fraction II; Sigma Chemical Co.) several times and incubated with 
anti-CD59 antiserum (diluted 1:1 in the above medium) for 30 min 
at 37~  After extensive washes, the parasites were further incubated 
with FITC-conjugated anti-rabbit IgG Ab (Bio-Yeda, Rehovot, Is- 
rael) diluted 1:10 in PBS for 30 min on ice. After additional washes, 
the schistosomula were fixed in 3% paraformaldehyde (BDH Lab- 
oratory Supplies,  Poole,  UK) for 1 h  on ice. AW were observed 
unfixed. Parasites were examined and photographed using a fluores- 
cence microscope (Photomicroscope III, Zeiss, Oberkder, Germany) 
and a Kodak 400 ASA film. 
Immunogold Labeling and Electron Microscopy.  24-h-old schisto- 
somula were washed with PBS and fixed with a mixture of 3% 
paraformaldehyde and 0.1% glutaraldehyde  (Polysciences Inc., War- 
rington,  PA) in PBS for 2 h at 4~  Cryosections were prepared 
as previously described (41). Immunolabeling was performed at room 
temperature according to the method of Tokuyasu and Singer (42), 
using rabbit anti-CD59 antiserum or NRbS (control) diluted 1:200 
in PBS and gold-conjugated protein A (15 nm; Zymed Laborato- 
ries Inc., S. San Francisco,  CA). Standard procedures for fixation, 
dehydration, and embedding in EPON 812 of the schistosomula 
were employed. Electron micrographs were obtained using an elec- 
tron microscope (EM410;  Philips Technologies, Cheshire, CT) at 
80 kV. 
Protein Determination, SDS-PAGE, and Western Blotting.  Protein 
concentration was measured by using Bio-Rad's protein assay dye 
reagent (Bio-Rad Laboratories)  according to manufacturer's instruc- 
tions.  Electrophoresis  was performed on  acrylamide gels under 
reducing or nonreducing conditions according to Laemmli (38). 
Molecular weight markers of Pharmacia LKB were used: phosphory- 
lase B (94,000),  BSA (67,000),  ovalbumin (43,000),  carbonic anhy- 
drase (30,000), soybean trypsin inhibitor (20,100), and cr 
(14,400). Nitrocellulose membranes (0.2/xm; Schleicher & Schuell, 
Inc., Keene,  NH) were used for Western blotting  according to 
Towbin  (43).  Membranes were blocked with  3%  BSA in  Tris- 
buffered saline (TBS-BSA).  Thereafter, anti-CD59-reactive bands 
were detected with polyclonal anti-human urine CD59 Ab (diluted 
1:300) or mAb YTH 53.1 (20/~g/ml), followed by 12sI-Protein A 
(200,000 cpm/ml). Membranes were dried and exposed to an X-ray 
film (Curix PP-2;  AGFA Corp., Orangeburg,  NY).  In some ex- 
periments, the enhanced chemiluminescence reagent (ECL; Amer- 
sham, International) was used according to manufacturer's instruc- 
tions. Detection of the positive bands in these blots was performed 
with horseradish peroxidase-conjugated goat anti-rabbit IgG Ab 
(Sigma Chemical Co.) and the ECL detection reagents. 
Immunoprecipitation.  Immunoprecipitation was carried out ac- 
cording to Kessler (44) with some modification. Briefly,  [3SS]me- 
thionine metabolically labeled schistosomula or AW NPRM (40 
#1) was mixed with 460/~1 ofS0 mM Tris HCI, pH 7.4, containing 
5  mM EDTA,  150  mM  NaC1,  and  0.5%  NP-40  and  40  #1  of 
anti-human CD59 antiserum or NRbS for 1 h on ice. After an 
additional incubation of 10 min on ice with 25/~1 of 10% (wt/vol) 
formalin-fixed Staphylococcus aureus (Sigma Chemical Co.), the bac- 
terial adsorbent was washed three times with the latter buffer con- 
taining 5% (wt/vol) sucrose.  After a final wash with 50 mM Tris 
HC1, pH 7.4, and 150 mM NaC1, the immunoprecipitates were 
resuspended in sample buffer (50 mM Tris, pH 6.8, 10% glycerol, 
4% SDS, and 5% fl-mercaptoethanol), boiled for 5 min, and sub- 
jected  to  SDS-PAGE  analysis  (38).  The  gel  was  stained  with 
coomassie blue  (Sigma Chemical Co.),  destained,  treated with 
DMSO and 2,5-diphenyloxazole (PPO) (Sigma Chemical Co.), and 
dried. Autoradiography was performed by exposure of Curix RP-2 
AGFA X-ray films to the dried gel at  -70~ 
Immunoaflinity Aclsorbtion.  12SI-NPRM prepared from surface- 
labeled schistosomula,  was mixed with noniodinated schistosomular 
NPRM at a 1:2 ratio and passed through a 2-ml affinity column 
composed of anti-CD59 Ig coupled to cyanogen bromide-activated 
Sepharose (Pharmacia LKB) or NRb-Ig-Sepharose. The unbound 
proteins were washed away extensively with 20 ml TBS (10 mM 
Tris,  150 mM NaC1) and then with 10 ml of TBS supplemented 
with 400 mM NaC1.  The column was washed again with 20 ml 
of TBS and eluted with 0.1  M  glycine-HC1, pH 2.5  containing 
0.01% NaN3. The pH of the eluted fractions (250/~l/tube)  was 
neutralized with 25 #1 of 1.5 M Tris, pH 8.8. The eluted fractions 
were dialyzed for 18 h at 4~  against GVB  2+ and tested for their 
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pooled, concentrated in a Speed Vac (Hetovac VR-1; Heto High 
Technology of Scandinavia, Birkerod, Denmark), and further ana- 
lyzed by SDS-PAGE and autoradiography. 
Binding of SCIP-1 to Human C8 and C9.  5/~g of human C8 
(a kind gift from Dr. J. M. Sodetz, University of South Carolina, 
Columbia, SC) and C9 were electrophoresed under nonreducing 
conditions on 7.5% acrylamide gels and transferred to nitrocellu- 
lose membranes (0.2 #m, Schleicher & Schuell). After blocking 
the membrane for 2 h at 24~  in TBS, pH 7.6 containing  5% 
skimmed milk (Marvel  Cadbury, Bournville,  UK) and 0.1% Tween- 
20 (Sigma Chemical Co.), it was incubated with schistosomular 
NPRM diluted 1:4 in blocking buffer containing protease inhibi- 
tors (10 mM PMSF [Sigma Chemical Co.], 10 mM EDTA [BDH 
Laboratory  Supplies] and 10/~g/ml aprotinin [Sigma Chemical Co.]) 
for 2 h at 37~  The membrane was extensively  washed and bound 
SCIP-1 was detected by using anti-human CD59 antisera and the 
ECL method as described for Western blotting. 
Anti-CD59  Abs were eluted from membrane strips (0.5  x  1 
cm) containing C9, SCIP-1, and bound Ab molecules with 0.2 M 
glycine-HC1, pH 2.6, for 1 h at room temperature, according to 
Ritter (45). The specificity of the eluted Ab to SCIP-1 was exam- 
ined by Western blotting of schistosomular extracts. 
Results 
Identification of  C Inhibitory Proteins on the Surface of  C-resistant 
Schistosomes.  Treatment  of  resistant  schistosumula  with 
trypsin renders them susceptible to complement killing (12). 
The trypsin's sensitizing effect on five different life cycle stages 
of S.  mansoni was examined (Table  1).  Freshly transformed 
(0 h), 4- and 24-h-old schistosomula, lung worms, and AW 
were treated with trypsin at various concentrations and their 
susceptibility to guinea pig C  was then measured.  Freshly 
transformed schistosomula showed high susceptibility to C 
even without any treatment and trypsin had hardly affected 
their sensitivity to C. 4- and 24-h-old schistosomula and AW 
became, upon trypsinization, susceptible to C-mediated killing. 
Trypsin concentrations of 250-500 ~g/ml produced maximal 
(100%) killing of the schistosomula and up to 65% killing 
of AW. Trypsin treatment had almost no effect on the inter- 
action of lung worms with GPS. We have previously sug- 
gested that schistosomula and AW express on their surface 
trypsin-sensitive C  inhibitory proteins (CIPs)  (12). 
The presence of a C  inhibitor on schistosomula was fur- 
ther indicated in experiments analyzing activation of the ter- 
minal C components. Successful activation of the C cascade 
culminates in generation of the MAC  and polymerization 
of C9 (13). The polymerized C9 (poly C9) has an apparent 
Mr  of ~106  and  is  resistant  to  boiling  in  reducing SDS- 
PAGE sample buffer. One way to determine the extent of 
C activation is to analyze poly C9 formation after inclusion 
of 12si-C9 in  the serum used as a C  source (46).  We have 
demonstrated formation of poly C9 on the surface of freshly 
transformed schistosomula incubated for 20 min with NHS 
(Fig.  1). Poly C9 formation was markedly reduced on 24 h 
schistosomula but trypsinization led to successful  polymer- 
ization of C9 on the same larvae (Fig.  1). 
The schistosomal TRM inhibited both classical and alter- 
native C pathways as demonstrated by its effect on the lysis 
of EAs and Ep. by NHS.  As shown in Fig.  2,  TRM from 
AW (AW/TRM) and schistosomula (S/TRM) inhibited both 
EAs lysis  (90 and 80%,  respectively) and Ep. lysis  (89 and 
36%, respectively), indicating inhibition of the two C lytic 
pathways. In contrast, trypsinization of cercaria has not pro- 
duced any inhibitory activity to sheep E hemolysis by NHS 
(not shown). NP-40 extracts of AW (AW/NP-40) inhibited 
EAs lysis (83% inhibition) as well. As shown here and in 
Table  1.  Trypsin-induced  Killing of Schistosomes by Complement 
Percent mortality* 
Schistosomula 
Trypsin*  0 h  4 h  24 h  Lung worms  Adult  worms 
~g/ml 
0  87  2  1  16  3 
50  100  42  51  4  17 
100  100  55  78  27  18 
250  ND  71  100  23  44 
500  ND  100  ND  28  65 
* Killing was performed  in GPS diluted 1:2 in DSM and percent  mortal- 
ity was calculated. 
Trypsinization was carried out for 30 min at 24~  in DSM. 
Figure 1.  C9 deposition  on schistosomula. Freshly  transformed  schis- 
tosomula (0'), 24-h-old  schistosomula  (24 h) and trypsinized  24-h-old  schis- 
tosomula (24-hT), were incubated with NHS supplemented  with 123I-C9 
for 20 min at 37~  Parasites were then washed in DSM, resuspended 
in reducing  sample  buffer,  boiled  for 10 min, and sonicated.  The resulting 
extracts were applied on a 2.5-10% gradient gel for SDS-PAGE  analysis. 
A representative  autoradiogram is shown. 
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Figure  2.  Inhibition of C-mediated hemolysis 
by membrane extracts of S. mansoni. 1.5  ￿  10  ~ 
EAs (A) or Ep. (B) in GVB  2§  were mixed with 
NHS diluted 1:80 in the absence or presence of 
membrane extracts and incubated for 30 min at 
37~  Unlysed Es were removed  by centrifugation 
and percent lysis was determined. Percent inhibi- 
tion of lysis relative to control without parasite 
extracts was calculated. Results represent means 
_+  SE of seven experiments. 
following experiments, NP-40 solubilized the AW membrane 
components  with  the  inhibitory  activity. 
Inhibition of  the Membrane  Attack Complex (MAC) of C.  To 
directly assess whether schistosomula and AW express an in- 
hibitor of MAC formation, we have examined the ability of 
parasite NP-40 extracts (NPRM)  to inhibit E lysis after for- 
mation of C5b-7 complexes. This was performed by prein- 
cubation of EAC5b-7 with schistosomular or AW NPRM, 
followed by addition of C7d-NHS  as the source of C  com- 
ponents C8 and C9.  As shown in Fig.  3 A, E lysis was in- 
hibited by NPRM  in a dose-dependent manner. Heat treat- 
ment (50~  and above) of the NPRM completely abolished 
its  inhibitory  effect  (Fig.  3  B).  Furthermore,  polyclonal 
monospecific anti-human CD59 Abs blocked the NPRM C 
inhibitory effect (Fig. 3 C). Preincubation of the NPRM with 
1.0 mg of anti-CD59  Ig decreased the extent  of inhibition 
by 77%  (from 94.4 to 23%).  No significant decrease of the 
NPRM-inhibitory effect was observed when the NPRM was 
incubated  with  1.0 mg of normal rabbit immunoglobulin. 
These results  establish  that  a protein  found  in  NPRM  ex- 
tracts of schistosomes, is capable of inhibiting formation of 
C  MAC, and is therefore termed SCIP-1, schistosome C  in- 
hibitory  protein  type-1.  SCIP-1  activity  may  be  blocked 
specifically by anti-human  CD59  Abs,  indicating  an  anti- 
genic  similarity  to  human  CD59. 
Induction of Schistosomacidal Activity with Anti-CD59 Abs. 
The finding  that  schistosomular  NPRM  inhibited  the  ter- 
minal C  pathway and that this C  inhibitory effect could be 
blocked specifically by anti-CD59 Abs led us to test whether 
the anti-CD59  Abs could block the MAC inhibitory mole- 
cule on the intact parasite surface and render the parasite sen- 
sitive to C killing. Incubating C resistant 24-h-old schistoso- 
mula with anti-CD59 Abs indeed sensitized the schistosomula 
to killing by GPS (Fig. 4 A). To exclude the possibility that 
the anti-CD59 Ab simply activated classical C  pathway, 24- 
h-old schistosomula were treated with F(ab')2 fragments of 
the anti-CD59 Abs that are not expected to induce classical 
C pathway activation. On addition of GPS, increasing levels 
of mortality  were  observed  (up  to  48%)  (Fig.  4  B).  Abs 
directed to the 28-kD  proteases, which  are known  to bind 
to the surface of 24-h old schistosomula (11) served as non- 
relevant control Ab and produced up to  18%  mortality of 
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Figure  3.  Inhibition of the C terminal pathway by parasitic NPRM. 
(.4)  EAC5b-7 (1.5  x  10~) were  treated  with  different amounts  of 
schistosomular (El) or AW NPRM ([~) for 15 min at 24~  Next, C7d- 
NHS was added and incubation continued for 30 min at 37~  Percent 
lysis was measured and percent inhibition relative to control without any 
NPRM was calculated. Results are mean of three experiments. (B) Heat 
inactivation of the inhibitor of MAC formation. Schistosomular (O) or 
AW NPRM (e) (50/A) were heated for 5 min at various temperatures 
and tested for their capacity to inhibit MAC formation as explained in 
A. (C) Neutralization of the MAC inhibitor with anti-CD59 Abs. Rabbit 
anti-CD59  Ig (I)  or normal rabbit (NRb) Ig (13) were mixed with 
schistosomular NPRM (20/~g) for 1 h at 24~  and then for 3 h on ice. 
1.5  x  10  ~ EAs and NHS (1:200 final dilution) were then added and in- 
cubation continued for 30 min at 37~  Percent inhibition was calculated. 
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Figure  4.  Antibodies to human CD59 induce 
killing of schistosomula  by GPS. 24-h-old schisto- 
somula were treated with increasing volumes of 
undiluted rabbit anti-CD59 antisera (A and C), 
NRbS (A and C), F(ab')2 fragments of the rabbit 
anti-CD59 Ab (B), or anti-28 kD protease  antisera 
(B), for 30 min at 24~  The schistosomula were 
then washed and killing was induced by GPS (.4 
and B), or C4d-GPS (C) for 18 h at 37~  Percent 
net mortality was calculated relative to controls 
with heat-inactivated  GPS. Results represent means 
_+  SD of three experiments. 
schistosomula (Fig. 4 B). Anti-28kD antibodies probably ac- 
tivated directly the classical complement pathway. Schistoso- 
mular killing with C4d-GPS which has no classical C pathway 
activity, was also induced by the anti-CD59 antiserum (Fig. 
4 C). F(ab')2 fragments of the anti-CD59 Ab-induced killing 
of schistosomula by human C  as well (Fig. 5). These results 
demonstrated killing of the schistosomula via the alternative 
pathway of guinea pig and human C,  effected by blocking 
the  activity  of SCIP-1,  with  anti-human  CD59  Abs. 
Antigenic  Competition  Between  human  CD59 and SCIP-1. 
Additional evidence supporting antigenic-cross-reactivity be- 
tween SCIP-1 and human CD59 was obtained by competing 
the  two  for binding  to anti-human  CD59  Abs.  The assay 
was performed as explained under  Materials  and Methods. 
As shown  in Table 2,  preincubation  of the  anti-CD59  an- 
tiserum (diluted 1:480) with human urine CD59 or E ghosts, 
reduced  its  binding  to  schistosomular  NPRM  by  "~50%. 
Binding of the antiserum diluted  1:960 and blocked with E 
and  urine  CD59  to  NPRM  was reduced  by 65  and  74%, 
respectively. Preincubation of the antiserum with schistoso- 
mular NPRM completely abolished its binding to the NPRM 
attached  to the microtiter plate.  These results indicate  that 
SCIP-1 shares antigenic epitopes with human CD59, but prob- 
ably contains  unique  parasitic  epitopes  as well. 
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Figure  5.  Killing of schistosomula  by anti-CD59 Abs and NHS. 24-h- 
old schistosomula  were treated with F(ab')2  fragments of rabbit anti-CD59 
Abs or NRbS as control for 30 min at 24~  and then with NHS for 18 h 
at 37~  Concentration of F(ab')2 was 50 #g/ml and NRbS and NHS 
were used undiluted. Results are of an experiment representative of three 
independent experiments. 
Localization of SCIP-1 in Schistosomula and AW.  The lo- 
calization  of SCIP-1 in the C-resistant  parasitic stages was 
first studied using intact parasites, rabbit anti-human CD59 
Abs, and the immunofluorescence technique (Fig. 6). Freshly 
transformed schistosomula, which are sensitive to C  attack, 
had almost no SCIP-1 on their surface, whereas 24-h-old schis- 
tosomula and 6-wk-old AW were stained nicely on their sur- 
face with the anti-CD59 Abs. Additional evidence confirming 
the presence of SCIP-1 on the surface of 24-h-old schistoso- 
Table  2.  Human  CD59 and SCIP-I  ComFete  for Binding to Anti-CD59  Ab 
1/Ab  Buffer  Human erythrocyte  Pure human  Schistosomular 
dilution*  alone  ghosts  urine  CD59  NPRM 
60  1,911'  1,025  1,021  70 
120  1,625  985  827  65 
240  1,365  607  746  72 
480  1,085  512  525  59 
960  957  332  249  57 
1,920  214  168  179  63 
* Rabbit anti-CD59 Abs were preincubated at varying dilutions with buffer alone, human erythrocyte ghosts (4.8/~g), purified human urine CD59 
(200 ng), or schistosomular NPRM (15 #g). The blocked Abs were then added to microtiter plate wells precoated with 15 #g schistosomular NPRM 
and incubated for 20 h. Ab binding was quantitated  with  12sI-Protein A. 
* Results are expressed as cpm of 12sI-Protein A bound to Abs in each well. Results represent a mean of triplicates in three different experiments. 
SD <2%. 
1630  CD59-1ike  Protein in Schistosoma mansoni Figure 6.  Immunofluorescence  staining of schistosomula  and AW with 
anti-CD59 Ab. Freshly  transformed  schistosomula (0'), 24-h-old  schisto- 
somula and 6-wk-old  in rive derived  adult worms  were  stained with rabbit 
anti-human CD59 Ab, and then with FITC-conjugated  goat anti-rabbit 
IgG and observed  under a fluorescence  microscope.  Bright and dark field 
representative exposures are shown. 
mula  was  obtained by  using  cryosectioning and  the  im- 
munogold labeling technique (Fig.  7). The electron micro- 
graphs  revealed  exclusive  presence of SCIP-1  on the outer 
membrane of the schistosomular tegument  (Fig.  7, B  and 
C). No gold particles could be detected within the tegument 
and the underlying muscle layers. Furthermore, control sec- 
tions treated with NRbS were clearly devoid of gold parti- 
cles  (Fig.  7 D). 
Identification of the Molecular Size of SCIP-I.  Anti-human 
CD59 polyclonal and monoclonal Abs were used to identify 
SCIP-1 by immunoprecipitation and Western blotting tech- 
niques (Fig.  8). 24-h-old schistosomula and AW were meta- 
bolically labeled with  [35S]methionine  and  extracted with 
NP-40. As shown in Fig.  8 A, a 94-kD band was immune- 
precipitated from both schistosomular  and AW NPRNI. Some 
of the 94-kD protein was also immunoprecipitated nonspecifi- 
cally (Fig. 8 A, lane 5), possibly due to weak binding of this 
protein to the bacterial adsorbent. A 94-kD protein was also 
identified  by  Western  blotting  using  polyclonal  anti- 
human urine CD59 Abs and a mAb YTH 53.1 raised against 
Figure 7.  Electron micrographs of 24-h-old 
schistosomula immunolabeled with anti-human 
CD59 Ab. Epon section  is shown in A. Cryosec- 
tions were treated  with rabbit anti-human CD59 
antiserum (B and C) or with NRbS (D) and then 
with  gold-conjugated protein A.  Sections are 
shown at different  magnifications:  (A) 6,900, (B) 
17,000, (C) 34,000, (D) 14,900. 
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protein band was detected, although occasionally an addi- 
tional band of 120 kD was observed.  The same protein pat- 
tern was obtained with schistosomular and AW TRM. The 
mobility of the 94-kD protein on SDS-PAGE gel remained 
unchanged under reducing conditions (data not shown). We 
have concluded that this 94-kD protein is SCIP-1. 
Partial Purification  of SCIP-1.  Since the polyclonal anti- 
human CD59 Abs bind well to SCIP-1 and are capable of 
blocking its C inhibitory effect, they served to affinity  purify 
the protein. IgG was partially purified from the anti-CD59 
antiserum (by precipitation in 50% ammonium sulphate) and 
coupled to cyanogen bromide-activated Sepharose beads. 24- 
h-old  schistosomula  were  surface  labeled  with  12si and 
NPRM was prepared.  A  mixture of 1/3  [12SI]NPRM and 
2/3 unlabeled NPRM was loaded onto the Ab column, and 
after extensive washing the bound protein was eluted with 
glycine-HC1, pH 2.5, and the pH was neutralized.  The eluted 
fractions were dialyzed for 18 h against GVB  2  § and exam- 
ined for C  inhibitory activity (not shown).  A  pool of the 
active eluted fractions was analyzed by SDS-PAGE (not shown) 
and autoradiography (Fig. 9 C). The same procedure was car- 
ried out using a nonrelevant affinity column containing normal 
rabbit Ig bound to Sepharose. Major bands of 94 and 82 kD 
were  observed  in  the  material  eluted  from  the  anti- 
CD59-Sepharose column (Fig.  9 C, lane 1).  It is possible 
that the 82-kD band observed in Fig. 9 C, lane 1, is a cleavage 
product of the 94-kD protein. The corresponding fractions 
of the normal rabbit IgG-Sepharose eluate were devoid of 
any protein (Fig. 9 C, lane 2). The effect of the columns eluates 
on lysis of EA and ER by NHS was next examined.  The ma- 
terial eluted from the NKb-IgG-Sepharose column had al- 
most no effect on EA and Ep, lysis. In contrast, the proteins 
eluted from the anti-CD59-Sepharose column, reduced EA 
lysis from 65  to 25%  (Fig.  9 A),  and Ep. lysis from 55  to 
20%  (Fig.  9 B). 
Binding of SCIP-1  to Human C8 and C9.  Human CD59 
binds the C components C8 and C9, thus restricting forma- 
tion of the MAC (29). We tested whether SCIP-1 can bind 
to the same C components (Fig. 10). Purified human C8 and 
C9 were electrophoresed under nonreducing conditions and 
transferred  to a nitrocellulose membrane. After blocking, the 
membrane was treated with schistosomular NPRM  (sup- 
plemented with protease inhibitors),  washed,  and further 
treated with anti-human CD59 Abs.  As shown in Fig.  10 
B, SCIP-1 bound to C8 (/3 subunit) and to C9 but not BSA. 
Other results have demonstrated that excess soluble C9 can 
block binding of SCIP-1  to electroblotted C9 (not shown). 
To further establish the identity of the C8/C9-binding pro- 
tein and the 94-kD SCIP-1, the Abs bound to the C9-binding 
protein were eluted from the nitrocellulose membrane with 
acidic buffer and reexamined by Western blotting on schisto- 
somular NPRM.  As shown in Fig.  10 D,  the eluted Abs 
specifically recognized in schistosomular NPRM the 94-kD 
SCIP-1. 
Release of  SCIP-1 with PI-PLC.  Human CD59 is anchored 
to cell membranes via a glycosyl  phosphatidylinositol anchor, 
and can be removed with PI-PLC (17, 47,  48).  We tested 
Figure  8.  Immunodetection  of SCIP-1 in schistosomular  and AW ex- 
tracts. (A) Immunoprecipitation  of [3sS]methionine-labeled  NPRM. Lane 
1, total  proteins  labeled  in schistosomular  NPRM. Lane  2, schistosomular 
NPRM immunoprecipitated  with anti-human  CD59 Abs. Lane  3, total 
proteins in labeled  AW NPRM. Lane  4, AW NPRM  immunoprecipitated 
with anti-human  CD59 Abs. Lane  5, AW NPRM immunoprecipitated 
with NRbS. All immunoprecipitates  were analyzed  on SDS-PAGE under 
reducing  conditions  (lanes 1-2, 5-15% gradient  gel; lanes  3-5, 12% gel). 
(B) Western blotting analysis.  Lanes  6 and 9, pure human urine CD59 
(200 ng); Lanes 7 and I0, normal  human  E ghosts; Lanes  8, 11, and I2, 
schistosomular  NPRM. Lanes  6-8 were treated  with polyclonal  anti-human 
urine CD59 Abs followed  with 125I-Protein  A. Lanes  9-11 were treated 
with NRbS followed  with 12sI-Protein A. Lane  12 was treated  with rat 
mAb YTH.53.1 followed  by peroxidase  goat anti-rat IgG conjugate  and 
developed using ECL reagents. Lane 13, normal human E ghosts. Lane 
14, AW TRM. Lanes 13 and 14 were treated with anti-CD59 Ab and 
12sI-Protein A. All Western blots were carried out after SDS-PAGE on 
12% gels under nonreducing  conditions. 
1632  CD59-1ike  Protein in Schistosoma mansoni supernatants  derived from schistosomula  incubated  in TBS 
alone (Fig. 11, lane 1). Also shown is the detection of human 
urine CD59  (Fig.  11,  lane 3)  and  SCIP-1  in  NPR.M  of 3  h 
old  schistosomula  (Fig.  11,  lane  4) by the  anti-CD59  Abs. 
These results suggest that SCIP-1 is PI-anchored to the schisto- 
somular  surface. 
Figure  9.  Af~nity purification of the SCIP-1. 24-h-old schistosomula 
were labeled with  12Sl and extracted with  NP-40. A mixture of [125I] 
NPRM (1/3) + unlabeled  NPRM (2/3) was loaded onto an affinity  column 
of anti-CD59 Ig-Sepharose  or normal rabbit lg-Sepharose.  The bound pro- 
teins were eluted with glycine-HCl, pH 2.5, and tested for their capacity 
to inhibit the classical (EAs lysis) or alternative (ER lysis) pathways of C. 
The pools of eluted anti-CD59 Sepharose  active fractions (m) and the cor- 
respondent NRbS Sepharose  eluted fractions ([~) were tested on EAs (A) 
or Er~ (B). Also shown is a control of buffer alone (I-7). The pools ot 
eluted active fractions were further subjected to SDS-PAGE  unreduced on 
a 12% gel and to autoradiography  (C). Lane 1, anti-CD59-Sepharose  ehate; 
lane 2, NRbS-Sepharose eluate. 
whether SCIP-1 is similarly anchored to the parasite's mem- 
brane. 24-h-old schistosomula were treated with Bacillus thurin- 
giensis PI-PLC (2.7 U/ml in TBS) (Oxford Glycosystems, Ltd., 
Abingdon,  UK), and the released material was subjected to 
electrophoresis  and Western blotting  analysis.  As shown in 
Fig. 11, anti-CD59 Abs detected in the PI-PLC-released ma- 
terial  a  94-kD  major protein  and  a  higher  molecular mass 
band (Fig.  11,  lane 2).  No protein could be detected in the 
Discussion 
Pathogenic  parasites  employ multiple  strategies  to  evade 
the  host's complement  system  (7)  and  in  general,  the  im- 
mune response (49). S. mansoni can successfully infect its per- 
missive mammalian hosts and resides for years within  their 
blood system in direct contact with the C  proteins. The mech- 
anisms whereby this parasite avoids C-mediated damage has 
intrigued us and others for several years now,  and it has be- 
come apparent  that  a combination  of several physical,  bio- 
chemical,  and  immunological  barriers  protects  the  parasite 
from C.  We  have hereby  described  a  novel  schistosome  C 
inhibitor,  SCIP-1, which  targets its inhibitory action at the 
terminal C  proteins C8 and C9 and thereby prevents forma- 
tion  of the  C  MAC. 
We have previously shown that treatment of schistosomula 
ofS. mansoni with trypsin or pronase sensitizes them to killing 
by the alternative C  pathway (12). This finding is confirmed 
now with adult worms, although higher trypsin concentra- 
tions are required for sensitization of AW than of schistoso- 
mula (Table 1).  Lung stage worms are much less affected by 
trypsin  (Table  1).  This  latter  result  is  in  agreement  with 
previous data indicating  that  the tegument  of lung worms 
is resistant to immune attack (50). Adherence of eosinophils, 
mediated by Ab or C receptors, which is lethal to young 3-h- 
Figure  10.  SCIP-1  binding to C8 and C9. Purified human C8 and C9 
and BSA (5/xg each) were subjected unreduced to SDS-PAGE (7.5% gel) 
and stained with coomassie  blue (/1) or transferred to nitrocellulose mem- 
branes (B and C). The membranes were blocked with milk and overlayed 
with (B) or without (C) schistosomular NPRM for 2 h at 37~  After 
extensive washes, anti-CD59 antisera (1:50) was added for 1 h at 24~ 
followed by horseradish peroxidase-conjugated goat anti-rabbit  IgG for 
45 rain. Detection was carried out with the ECL kit. Molecular masses: 
lane 1, BSA, 67 kD; lane 2, human C8 a,3~ subunit, 86 kD,/~ subunit, 
68 kD; lane 3, human C9,  71 kD.  (]9) Antibodies were eluted from a 
nitrocellulose strip of C9-bound NPRM and Ab-treated membrane and 
treated by Western blotting  on schistosomular NPRM. After blocking, 
the membrane containing the NPILM was overlayed  with the eluted Ab 
for 18 h at 24~  washed, and Ab binding was detected  using the peroxidase- 
conjugated goat anti-rabbit IgG and the ECL kit (lane 4). NKbS, instead 
of the eluted Abs, served as a negative control  (lane 5). 
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Figure  11.  Removal  of SCIP-1 
with PI-PLC. Samples  of 24-h-old 
(100,000) schistosomula were ei- 
ther untreated (lane 1) or treated 
with PI-PLC (2.7 U/ml) in TBS 
for 1.5 h at 37~  (lane 2). After 
treatment, the schistosomuh were 
removed and supernatant applied 
unreduced to a 12% SDS-PAGE 
gel. Also shown are pure human 
urine CD59 (200 ng) (lane 3) and 
NPRM  prepared  from  3-h-old 
schistosomula (lane 4).  Proteins 
separated on the gel were trans- 
ferred to nitrocellulose paper and 
detected using anti-CD59 anfisera 
(diluted 1:300) followed by 1251- 
Protein A (8  x  105 cpm/ml). An 
autoradiogram is shown. old schistosomula, does not occur when 4-d-old lung worms 
are used as targets  (51). It has been claimed that the lung 
worms have low surface antigenicity and do not promote 
effector mechanisms involving recognition and direct surface 
damage (50). It may be suggested now that lung worms ei- 
ther lack C activating substances on their surface, or express 
potent trypsin-resistant  C  inhibitors. 
The finding that trypsinization has markedly  enhanced the 
generation of complement MAC (formation of poly C9) on 
schistosomula  (Fig. 1), has implied that the schistosomula 
contain an external MAC inhibitory protein. In agreement, 
we could demonstrate that TRM and NPRM from shistoso- 
mula and AW can inhibit C-mediated hemolysis by both clas- 
sical and alternative pathways. Other results have clearly in- 
dicated that the inhibitor can block MAC formation even 
after generation of the C5b-7 complex (Fig. 3), namely at 
the C8 and C9 level. CD59 is a known mammalian protein 
capable of binding to C8 and C9 and preventing MAC for- 
mation (17, 23, 29). It is present on erythrocytes, leukocytes 
and many other cell types (24). We have undertaken to de- 
termine whether the schistosomula express a CD59-1ike pro- 
tein. Results have shown that indeed, antibodies directed to 
human CD59 bind to intact schistosomula  and AW and poten- 
tiate schistosomacidal activity of guinea pig and human C 
(Figs. 4 and 5). Furthermore, anti-CD59 Ab could block the 
C inhibitory activity of schistosomular NPRM. Immunogold 
labeling of cryosections of schistosomula have identified the 
CD59-1ike protein exclusively  on the tegumental outer mem- 
brane (Fig. 7). Based on immunoprecipitation and Western 
blotting analysis of schistosomular and AW extracts, we have 
concluded that the parasite CD59-1ike molecule is a 94-kD 
protein with few, if any, disulfide  bonds. It was named SCIP-1, 
abbreviated for schistosome C inhibitory protein type 1. The 
C-inhibitory activity of SCIP-1 is highly sensitive to heat 
treatment. 
Additional evidence illustrating functional similarity be- 
tween human CD59 and SCIP-1 is their binding to C8 and 
C9 (23) (Fig.  10 B). It has been postulated  that upon this 
binding of CD59, insertion of C9 into membranes and in- 
teraction  with C5b-8  complexes is inhibited (23,  29,  30). 
Specific  binding of human CD59 to C8 and C9 was detected 
only when these human C proteins were adsorbed to either 
plastic or nitrocellulose,  suggesting that a conformational 
change that accompanies surface adsorption exposes a CD59- 
binding site that is normally buried in these serum proteins 
(52). Similar to CD59, SCIP-1 binds to nitrocellulose-fixed 
C8 and C9, but the fact that soluble C9 can compete for 
binding of SCIP-1  to membrane bound C9,  suggests that 
SCIP-1 recognizes native epitopes of C9. In addition, SCIP-1 
binds primarily to the/3-subunit of C8, whereas CD59 binds 
to the ~  subunit of C8 (52). 
Another feature common to CD59 and SCIP-1 is their 
attachment to membranes via a linker sensitive to PI-PLC 
(31) (Fig. 11). The fact that PI-PLC treatment sensitizes schis- 
tosomula to killing by human complement (Ghendler, Y., 
and Z. Fishelson, unpublished data) further emphasizes the 
contribution of SCIP-1 to complement resistance in S. man- 
SCIP-1 is much larger than CD59 (18-20 kD), yet high mo- 
lecular weight proteins (80 kD) have also been immunopre- 
cipitated with anti-CD59 Abs from human cell lysates (17, 
22, 53). Although remote, we still have to consider the pos- 
sibility that SCIP-1 is composed of two or more molecules 
held together by SDS- and mercaptoethanol-resistant bonds. 
Paramyosin is a schistosome 94-kD  protein that was re- 
cently described as a possible C regulator (54). Paramyosins 
ofS. mansoni and of Taenia solium are capable of  binding com- 
plement C1, and inhibiting the classical C pathway. The pos- 
sible relationship between paramyosin to SCIP-1 was there- 
fore assessed. By Western blotting analysis, no cross-reaction 
between the two proteins  was detected (Parizade, M., R. 
Arnon, and Z. Fishelson, unpublished data). Anti-CD59 Abs 
do not recognize paramyosin and anti-pararnyosin Abs do not 
bind  to  SCIP-1.  Furthermore, it  has been  reported that 
paramyosin binds C1 exclusively and does not inhibit the al- 
ternative C pathway (54). In contrast,  SCIP-1 binds C8 and 
C9, thus inhibiting both classical and alternative C pathways. 
Moreover, SCIP-1 is located on the parasite surface, whereas 
paramyosin is an intramuscular  protein. 
Other parasites have also been reported to evade C destruc- 
tion by specifically  reacting with components of the terminal 
C pathway. The E. histolytica 260-kD galactose adhesion mol- 
ecule has limited sequence identity to human CD59 and ex- 
hibits a C5b-9 inhibitory activity (27). This adhesion mole- 
cule is capable of binding the terminal C components C8 
and C9 and confers upon reconstitution C5b-9 resistance on 
sensitive amoeba (27). A gene encoding a protein with 48% 
identity in its amino acid sequence to human CD59 has re- 
cently been found in the genome of H. saimiri (28). The site 
of expression and biological activity of this CD59-1ike pro- 
tein have not been determined yet. The T. cruzi amastigotes 
express probably a surface protein that inhibits the lytic ac- 
tivity of C5b-9 complex (55). The lipophosphoglycan (LPG) 
of Leishmania major is thought to inhibit proper membrane 
insertion of C5b-9 complexes (56, 57). It has also been pro- 
posed that elongation and compositional changes of the LPG 
on C resistant promastigotes, sterically  interfere  with the access 
of the C5b-9  macromolecules  to  the parasite membrane, 
thereby preventing channel formation and lysis  by MAC (58). 
Human CD59 is reported to have other functions in var- 
ious tissues, in addition to its role in restricting assembly of 
the cytolytic C5b-9. On human endothelial cells, CD59 was 
suggested to attenuate the capacity of C5b-9 to evoke throm- 
bogenic responses (59). On human blood platelets, CD59 
normally serves to attenuate the procoagulant  responses of 
these cells exposed to activated complement proteins  (60). 
More thoroughly investigated is the role of CD59 on human 
T cells. It has been suggested that CD59 on these cells serves 
as a physiological signaling receptor, mAbs to CD59 have 
been reported to initiate signal transduction events in T cells 
(61, 62) and CD59 was found to be associated with a tyrosin 
kinase implicated in T cell signaling (63). CD59 was shown 
to interact with CD2 and contribute together with CD58 
to T cell activation and adhesion (64, 65). Whether any of 
these human CD59 functions is also expressed by SCIP-1 is 
soni. The structure of the lipid anchor of SCIP-1 has not been  yet to be determined. 
studied yet and cannot be compared with that of CD59 (48). 
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